Health | The Business Standard
Skip to main content
  • Latest
  • Economy
    • Banking
    • Stocks
    • Industry
    • Analysis
    • Bazaar
    • RMG
    • Corporates
    • Aviation
  • Videos
    • TBS Today
    • TBS Stories
    • TBS World
    • News of the day
    • TBS Programs
    • Podcast
    • Editor's Pick
  • World+Biz
  • Features
    • Panorama
    • The Big Picture
    • Pursuit
    • Habitat
    • Thoughts
    • Splash
    • Mode
    • Tech
    • Explorer
    • Brands
    • In Focus
    • Book Review
    • Earth
    • Food
    • Luxury
    • Wheels
  • Subscribe
    • Get the Paper
    • Epaper
    • GOVT. Ad
  • More
    • Sports
    • TBS Graduates
    • Bangladesh
    • Supplement
    • Infograph
    • Explainer
    • Archive
    • Gallery
    • Long Read
    • Interviews
    • Offbeat
    • Magazine
    • Climate Change
    • Health
    • Cartoons
  • বাংলা
The Business Standard

Thursday
December 25, 2025

Sign In
Subscribe
  • Latest
  • Economy
    • Banking
    • Stocks
    • Industry
    • Analysis
    • Bazaar
    • RMG
    • Corporates
    • Aviation
  • Videos
    • TBS Today
    • TBS Stories
    • TBS World
    • News of the day
    • TBS Programs
    • Podcast
    • Editor's Pick
  • World+Biz
  • Features
    • Panorama
    • The Big Picture
    • Pursuit
    • Habitat
    • Thoughts
    • Splash
    • Mode
    • Tech
    • Explorer
    • Brands
    • In Focus
    • Book Review
    • Earth
    • Food
    • Luxury
    • Wheels
  • Subscribe
    • Get the Paper
    • Epaper
    • GOVT. Ad
  • More
    • Sports
    • TBS Graduates
    • Bangladesh
    • Supplement
    • Infograph
    • Explainer
    • Archive
    • Gallery
    • Long Read
    • Interviews
    • Offbeat
    • Magazine
    • Climate Change
    • Health
    • Cartoons
  • বাংলা
THURSDAY, DECEMBER 25, 2025

Health

Health

The logo of pharmaceutical company Novo Nordisk is displayed in front of its offices in Bagsvaerd, on the outskirts of Copenhagen, Denmark, December 3, 2025. Photo: REUTERS/Tom Little

What Novo Nordisk's weight-loss pill approval means for company, patients

The first GLP-1 pill specifically for obesity, also branded as Wegovy, is a 25-mg oral formulation of semaglutide, the active ingredient in the blockbuster injectable version

Boxes of Wegovy made by Novo Nordisk are seen at a pharmacy in London, Britain March 8, 2024. Photo: REUTERS/Hollie Adams/File Photo

Novo Nordisk wins US approval for weight-loss pill

TBS Illustration

Big players reshaping Bangladesh's retail pharmacy landscape

Representational image. Photo: Freepik

Magnesium deficiency: 5 silent signs you should never ignore

Illustration: TBS

2 dengue patients die, 194 fresh cases detected overnight

Photo: Collected

Feeling tired and sleepy during winter? Know why getting extra rest in colder months is important for your energy

Photo: Collected

Zinc for immunity: Doctor explains 5 ways to beat cold and flu faster in winter

Photo: Collected

Bangladesh's first national EQ-5D health value set unveiled

Photo: Collected

Cannabis-based drugs show early promise against ovarian cancer, researchers say

Khalil was asked to pretend it was his birthday. Photo: Collected

BBC investigation uncovers cancer fundraiser scam targeting children

Photo: Collected

Fertility specialist shares 5 unhealthy lifestyle habits that cause infertility

Representational image. Photo: Freepik

Cardiologist reveals the 'most powerful medicine' for your brain, heart

Illustration: TBS

Dengue: 5 more deaths, 387 hospitalised in 24hrs

  • Show More
EMAIL US
contact@tbsnews.net
FOLLOW US
WHATSAPP
+880 1847416158
The Business Standard
  • About Us
  • Contact us
  • Sitemap
  • Advertisement
  • Privacy Policy
  • Comment Policy
Copyright © 2025
The Business Standard All rights reserved
Technical Partner: RSI Lab

Contact Us

The Business Standard

Main Office -4/A, Eskaton Garden, Dhaka- 1000

Phone: +8801847 416158 - 59

Send Opinion articles to - oped.tbs@gmail.com

For advertisement- sales@tbsnews.net